Go Pro
→ 4th of July Chaikin flash sale (From Chaikin Analytics) (Ad)tc pixel
NYSE:BHVN

Biohaven Q3 2025 Earnings Report

Biohaven logo
$15.93 -0.03 (-0.19%)
Closing price 07/2/2026 03:59 PM Eastern
Extended Trading
$15.98 +0.05 (+0.31%)
As of 07/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Biohaven EPS Results

Actual EPS
-$1.64
Consensus EPS
-$1.91
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Biohaven Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.34 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biohaven Announcement Details

Quarter
Q3 2025
Date
11/10/2025
Time
Before Market Opens
Conference Call Date
Monday, November 10, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Biohaven's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Biohaven's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Biohaven's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Biohaven Earnings Headlines

Financial Review: Biohaven (NYSE:BHVN) versus Immunocore (NASDAQ:IMCR)
July 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30874603
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
June 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biohaven-completes-enrollment-in-rise-3-pivotal-focal-epilepsy-study-with-opakalim-a-selective-kv7-27-3-activator-302813944.html
Sell Tesla, Buy the New King of FSD Cars
In 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.tc pixel
 |  Chaikin Analytics (Ad)
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
June 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30869665
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
June 29, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/downgrades/26/06/60168944/analyst-warns-biohavens-lead-drug-may-struggle-to-stand-out?utm_source=snapi
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
June 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biohaven-advances-a-new-class-of-precision-immunology-therapies-first-mode-extracellular-protein-degrader-bhv-1300-begins-phase-3-pivotal-trial-in-graves-disease-302812720.html
See More Biohaven Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biohaven? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biohaven and other key companies, straight to your email.

About Biohaven

Biohaven (NYSE:BHVN) (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine. Its lead product, rimegepant—commercially marketed under the name NURTEC® ODT—has been approved for both acute migraine relief and migraine prevention in adults. Biohaven’s pipeline also includes atogepant, a once-daily oral CGRP receptor antagonist in late-stage development for migraine prevention, as well as earlier-stage candidates targeting N-methyl-D-aspartate (NMDA) receptors for chronic pain and other neurological disorders.

In addition to its internal programs, Biohaven has established global licensing agreements and co-development partnerships to expand the reach of its migraine therapies in key markets such as Europe, Canada and Asia. The company leverages a hybrid model of in-house development and external collaborations to accelerate clinical progress and broaden patient access.

Under the leadership of Founder and Chief Executive Officer Dr. Vlad Coric, Biohaven has built a multidisciplinary management team with deep experience in neuroscience drug development and commercial operations. Together, they aim to advance the company’s portfolio through late-stage clinical trials and regulatory submissions, with the goal of delivering novel treatments that improve patient outcomes in neurological and central nervous system disorders.

View Biohaven Profile
Earnings Tools